US FDA approves Lilly's Mounjaro to reduce cardiovascular risk
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
🌍 Cross-language spread
This story first appeared in 🇪🇸 Spanish coverage — 4.7 hours before PULSE detected it in English news.
Detected by matching proper nouns and figures that survive translation. Times reflect when each edition's coverage was first indexed.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"US FDA approves Lilly's Mounjaro to reduce cardiovascular risk" is generating significant coverage in the Business category, with 5 articles from 5 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Bloomberg.com, Harvard Health, Fierce Pharma and Eli Lilly and Company. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 80d ago.
Quick answers
Why is "US FDA approves Lilly's Mounjaro to reduce cardiovascular risk" trending?
Because 5 independent news sources published 5 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (9)
- Mounjaro Is Now Approved to Lower the Risk of Heart Events Time Magazine · 80d ago
- Eli Lilly's diabetes drug Mounjaro gets approval for a new use USA Today · 80d ago
- Eli Lilly's diabetes drug wins FDA approval to lower heart attack and stroke risk qz.com · 80d ago
- Tirzepatide Gets FDA Approval to Cut Cardiovascular Risk in Type 2 Diabetes HCPLive · 80d ago
- Lilly Diabetes Shot Mounjaro Wins US Approval for Heart Disease Bloomberg.com · 80d ago
- Weight-loss drug may lower risk of heart attacks and infections Harvard Health · 80d ago
- Lilly scores Novo-pressuring Mounjaro expansion to curb heart risks in diabetes patients Fierce Pharma · 80d ago
- FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes Eli Lilly and Company · 80d ago
- US FDA approves Lilly's Mounjaro to reduce cardiovascular risk Reuters · 80d ago
Topics
Related trends
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.
FDA rejects Summit’s ivonescimab, derailing US arrival of much-hyped PD-1xVEGF class
The United States Food and Drug Administration has rejected Summit Therapeutics and Akeso's lung cancer drug ivonescimab.
EXCLUSIVE: US FDA shelves commissioner's voucher program for speedy drug reviews, sources say
The US FDA has shelved its commissioner's priority review voucher pilot program for expedited drug reviews, according to exclusive reporting from Reuters and coverage across multiple outlets.
Former Eli Lilly rep claims she was fired for complaining about marketing of Mounjaro diabetes drug
A former Eli Lilly sales representative has filed a retaliation lawsuit alleging she was fired for objecting to Mounjaro marketing.